Loading
A phase 2 trial of gemcitabine, oxaliplatin and afatinib in gallbladder cancer, run by Shanghai Jiao Tong University School of Medicine, now recruiting.
Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA is a phase 2, randomised interventional study registered as NCT04183712 by Shanghai Jiao Tong University School of Medicine, with a registry enrolment figure of 102 participants, started 2020-06-01 and due to reach its primary completion in 2025-06. Interventions recorded: gemcitabine and oxaliplatin., Afatinib. Conditions listed: Gallbladder Carcinoma. Sites: China. No results are recorded here; the registry entry is the source.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.